287 related articles for article (PubMed ID: 32161055)
21. Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodYnamic long-term efficacy (ITALY study).
D'Alto M; Romeo E; Argiento P; Paciocco G; Prediletto R; Ghio S; Correale M; Lo Giudice F; Badagliacca R; Greco A; Vizza CD
J Cardiovasc Med (Hagerstown); 2018 Jan; 19(1):12-17. PubMed ID: 29215546
[TBL] [Abstract][Full Text] [Related]
22. Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.
Hassoun PM; Zamanian RT; Damico R; Lechtzin N; Khair R; Kolb TM; Tedford RJ; Hulme OL; Housten T; Pisanello C; Sato T; Pullins EH; Corona-Villalobos CP; Zimmerman SL; Gashouta MA; Minai OA; Torres F; Girgis RE; Chin K; Mathai SC
Am J Respir Crit Care Med; 2015 Nov; 192(9):1102-10. PubMed ID: 26360334
[TBL] [Abstract][Full Text] [Related]
23. Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysis.
Distler O; Ofner C; Huscher D; Jordan S; Ulrich S; Stähler G; Grünig E; Held M; Ghofrani HA; Claussen M; Lange TJ; Klose H; Rosenkranz S; Vonk-Noordegraaf A; Vizza CD; Delcroix M; Opitz C; Pausch C; Scelsi L; Neurohr C; Olsson KM; Coghlan JG; Halank M; Skowasch D; Behr J; Milger K; Remppis BA; Skride A; Jureviciene E; Gumbiene L; Miliauskas S; Löffler-Ragg J; Wilkens H; Pittrow D; Hoeper MM; Ewert R
Rheumatology (Oxford); 2024 Apr; 63(4):1139-1146. PubMed ID: 37462520
[TBL] [Abstract][Full Text] [Related]
24. Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension.
D'Alto M; Badagliacca R; Argiento P; Romeo E; Farro A; Papa S; Sarubbi B; Russo MG; Vizza CD; Golino P; Naeije R
Chest; 2020 Feb; 157(2):376-383. PubMed ID: 31563498
[TBL] [Abstract][Full Text] [Related]
25. Real-World Treatment Patterns Among Patients with Connective Tissue Disorder-Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis.
Sargent T; Tsang Y; Panjabi S; Funtanilla V; Germack HD; Gauthier-Loiselle M; Manceur AM; Cloutier M; Lefebvre P
Adv Ther; 2023 Nov; 40(11):5037-5054. PubMed ID: 37728697
[TBL] [Abstract][Full Text] [Related]
26. Initial dual oral combination therapy in pulmonary arterial hypertension.
Sitbon O; Sattler C; Bertoletti L; Savale L; Cottin V; Jaïs X; De Groote P; Chaouat A; Chabannes C; Bergot E; Bouvaist H; Dauphin C; Bourdin A; Bauer F; Montani D; Humbert M; Simonneau G
Eur Respir J; 2016 Jun; 47(6):1727-36. PubMed ID: 26989105
[TBL] [Abstract][Full Text] [Related]
27. Recent advances in the management of pulmonary arterial hypertension: lessons from the upfront combination of ambrisentan and tadalafil.
Escribano Subías P; Aurtenetxe Pérez A; Pérez Olivares C; Gómez Climent L; Diago Cabezudo JI; Perelló MF
Expert Rev Respir Med; 2021 Apr; 15(4):493-504. PubMed ID: 33472458
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
Huo Y; Jing ZC; Zeng XF; Liu JM; Yu ZX; Zhang GC; Li Y; Wang Y; Ji QS; Zhu P; Wu BX; Zheng Y; Wang PP; Li J
BMC Cardiovasc Disord; 2016 Oct; 16(1):201. PubMed ID: 27770771
[TBL] [Abstract][Full Text] [Related]
29. Pulmonary arterial hypertension in connective tissue diseases.
Goldberg A
Cardiol Rev; 2010; 18(2):85-8. PubMed ID: 20160534
[TBL] [Abstract][Full Text] [Related]
30. Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review.
Peacock AJ; Zamboni W; Vizza CD
Curr Med Res Opin; 2015; 31(9):1793-807. PubMed ID: 26196225
[TBL] [Abstract][Full Text] [Related]
31. Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.
Ivy D; Beghetti M; Juaneda-Simian E; Ravindranath R; Lukas MA; Machlitt-Northen S; Scott N; Narita J; Berger RMF
Eur J Pediatr; 2024 May; 183(5):2141-2153. PubMed ID: 38366267
[TBL] [Abstract][Full Text] [Related]
32. Do Patients With Low-Risk Pulmonary Arterial Hypertension Really Benefit From Upfront Combination Therapy?: Insight From the AMBITION Trial.
Fauvel C; Liu Y; Correa-Jaque P; Kanwar MK; Vizza CD; Lin S; Benza RL
Chest; 2023 Dec; 164(6):1518-1530. PubMed ID: 37356711
[TBL] [Abstract][Full Text] [Related]
33. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry.
Chung L; Farber HW; Benza R; Miller DP; Parsons L; Hassoun PM; McGoon M; Nicolls MR; Zamanian RT
Chest; 2014 Dec; 146(6):1494-1504. PubMed ID: 24992469
[TBL] [Abstract][Full Text] [Related]
34. Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China.
Zhao J; Wang Q; Liu Y; Tian Z; Guo X; Wang H; Lai J; Huang C; Yang X; Li M; Zeng X
Int J Cardiol; 2017 Jun; 236():432-437. PubMed ID: 28159359
[TBL] [Abstract][Full Text] [Related]
35. Undiagnosed connective tissue diseases: High prevalence in pulmonary arterial hypertension patients.
Cavagna L; Codullo V; Ghio S; Scirè CA; Guzzafame E; Scelsi L; Rossi S; Montecucco C; Caporali R
Medicine (Baltimore); 2016 Sep; 95(39):e4827. PubMed ID: 27684814
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological management of connective tissue disease-associated pulmonary arterial hypertension.
Kularatne M; Boucly A; Savale L; Solinas S; Cheron C; Roche A; Jevnikar M; Jaïs X; Montani D; Humbert M; Sitbon O
Expert Opin Pharmacother; 2023; 24(18):2101-2115. PubMed ID: 37869785
[TBL] [Abstract][Full Text] [Related]
37. Immunosuppressive therapy in patients with connective tissue disease-associated pulmonary arterial hypertension: A systematic review.
Ding Y; Qian J; Zhang S; Xu D; Leng X; Zhao J; Wang Q; Zhang W; Tian X; Li M; Zeng X
Int J Rheum Dis; 2022 Sep; 25(9):982-990. PubMed ID: 35699128
[TBL] [Abstract][Full Text] [Related]
38. Correction:
Ann Rheum Dis; 2020 Sep; 79(9):e118. PubMed ID: 32816781
[No Abstract] [Full Text] [Related]
39. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.
Oudiz RJ; Galiè N; Olschewski H; Torres F; Frost A; Ghofrani HA; Badesch DB; McGoon MD; McLaughlin VV; Roecker EB; Harrison BC; Despain D; Dufton C; Rubin LJ;
J Am Coll Cardiol; 2009 Nov; 54(21):1971-81. PubMed ID: 19909879
[TBL] [Abstract][Full Text] [Related]
40. Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan.
Shapiro S; Pollock DM; Gillies H; Henig N; Allard M; Blair C; Anglen C; Kohan DE
Am J Cardiol; 2012 Nov; 110(9):1373-7. PubMed ID: 22858181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
